Calcitonin Gene-Related Peptide
"Calcitonin Gene-Related Peptide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 37-amino acid peptide derived from the calcitonin gene. It occurs as a result of alternative processing of mRNA from the calcitonin gene. The neuropeptide is widely distributed in the brain, gut, perivascular nerves, and other tissue. The peptide produces multiple biological effects and has both circulatory and neurotransmitter modes of action. In particular, it is a potent endogenous vasodilator.
| Descriptor ID |
D015740
|
| MeSH Number(s) |
D12.644.400.097 D12.776.631.650.097
|
| Concept/Terms |
Calcitonin Gene-Related Peptide- Calcitonin Gene-Related Peptide
- Calcitonin Gene Related Peptide
- Gene-Related Peptide, Calcitonin
- Peptide, Calcitonin Gene-Related
|
Below are MeSH descriptors whose meaning is more general than "Calcitonin Gene-Related Peptide".
Below are MeSH descriptors whose meaning is more specific than "Calcitonin Gene-Related Peptide".
This graph shows the total number of publications written about "Calcitonin Gene-Related Peptide" by people in this website by year, and whether "Calcitonin Gene-Related Peptide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2008 | 0 | 4 | 4 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 2 | 0 | 2 |
| 2014 | 3 | 2 | 5 |
| 2015 | 5 | 1 | 6 |
| 2016 | 1 | 2 | 3 |
| 2017 | 4 | 0 | 4 |
| 2018 | 3 | 7 | 10 |
| 2019 | 5 | 5 | 10 |
| 2020 | 3 | 3 | 6 |
| 2021 | 1 | 4 | 5 |
| 2022 | 3 | 5 | 8 |
| 2023 | 0 | 3 | 3 |
| 2024 | 3 | 2 | 5 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Calcitonin Gene-Related Peptide" by people in Profiles.
-
Guzman G, Kopruszinski CM, Barber KR, Lillo Vizin RC, Dodick DW, Navratilova E, Porreca F. Chronification of migraine sensitizes to CGRP in male and female mice. Cephalalgia. 2025 Feb; 45(2):3331024251317446.
-
Alabbad S, Figueredo N, Yuan H, Silberstein S. Developments in targeting calcitonin gene-related peptide. Expert Rev Neurother. 2024 May; 24(5):477-485.
-
Chiang CC, Porreca F, Robertson CE, Dodick DW. Potential treatment targets for migraine: emerging options and future prospects. Lancet Neurol. 2024 Mar; 23(3):313-324.
-
Porreca F, Navratilova E, Hirman J, van den Brink AM, Lipton RB, Dodick DW. Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex. Cephalalgia. 2024 Mar; 44(3):3331024241238153.
-
Chhabra N, Mead-Harvey C, Dodoo CA, Iser C, Taylor H, Chaudhary H, Vanood A, Dodick DW. Blood pressure elevation in erenumab-treated patients with migraine: A retrospective real-world experience. Headache. 2024 03; 64(3):233-242.
-
Ashina M, Hoffmann J, Ashina H, Hay DL, Flores-Montanez Y, Do TP, De Icco R, Dodick DW. Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside. Mayo Clin Proc. 2024 Feb; 99(2):285-299.
-
Ceriani CEJ. Vestibular Migraine Pathophysiology and Treatment: a Narrative Review. Curr Pain Headache Rep. 2024 Feb; 28(2):47-54.
-
Porreca F, Dodick DW. Considering Patient Sex in Prescribing CGRP Receptor Antagonists for Short-Term Treatment of Migraine. JAMA Neurol. 2023 09 01; 80(9):885-886.
-
George N, Tepper SJ. Novel Migraine Treatments: A Review J Oral Facial Pain Headache. 2023; 37(1):25-32.
-
Silberstein SD, Reshef S, Cohen JM, Gandhi S, Seminerio M, Ramirez Campos V, Kessler Y, Thompson SF, Blumenfeld A. Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System. Adv Ther. 2023 02; 40(2):445-459.